|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
In a cohort of patients diagnosed with acute kidney injury after cardiopulmonary bypass surgery, the decreased TG and cholesterol negatively correlated with increased EPO in serum.
|
31740386 |
2019 |
|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erythropoietin modulates macrophages but not post-ischemic acute kidney injury in mice.
|
30414800 |
2019 |
|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endogenous Erythropoietin and Hepatic Dysfunction in Acute Kidney Injury Requiring Renal Replacement Therapy.
|
30712038 |
2019 |
|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Erythropoietin in traumatic brain injury associated acute kidney injury: A randomized controlled trial.
|
30132785 |
2019 |
|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Data showed that EPO attenuates renal microvascular damage during septic-AKI progression through a) the decrease of HIF-1 alpha, iNOS, and NF-κB and b) the enhancement of EPO-R, PeCAM-1, VEGF, and VEGFR-2 expression.
|
30257316 |
2018 |
|
Kidney Failure, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we tested whether an acute increase of plasma erythropoietin induces FGF23 expression in erythropoietic cells of bone marrow thereby contributing to the increase of circulating FGF23 in AKI.
|
29395333 |
2018 |
|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with placebo, the odds ratio (OR) for the occurrence of AKI was 0.24 [95% confidence interval (CI) 0.16-0.34] with natriuretic peptide, 0.33 (95% CI 0.14-0.70) with fenoldopam, 0.54 (95% CI 0.31-0.84) with dexmedetomidine, 0.56 (95% CI 0.29-0.95) with low-dose erythropoietin, 0.63 (95% CI 0.43-0.88) with levosimendan, 0.76 (95% CI 0.52-1.10) with steroids, 0.83 (95% CI 0.48-1.40) with high-dose erythropoietin, 0.85 (95% CI 0.64-1.14) with N-acetylcysteine, 0.96 (95% CI 0.69-1.29) with sodium bicarbonate, and 1.05 (95% CI 0.70-1.41) with statins.
|
28819767 |
2018 |
|
Kidney Failure, Acute
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Critically ill patients (AKI and non-AKI groups) had higher serum levels of Epo than healthy volunteers.
|
23566289 |
2018 |
|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, in the present study, we determined whether EPO could exert an impact on the dynamics of macrophages in a well-established model of rhabdomyolysis-induced acute kidney injury and explored the potential mechanisms.
|
28383559 |
2017 |
|
Kidney Failure, Acute
|
0.400 |
Biomarker
|
disease |
BEFREE |
Based on the results here, we conclude that HEPC, EPO and HIF-1α are involved in the pathogenesis of sepsis-induced AKI and confirm the dominating effects of inflammatory determinants over hypoxia-related complications.
|
27266727 |
2016 |
|
Kidney Failure, Acute
|
0.400 |
Therapeutic
|
disease |
CTD_human |
This study suggests that EPO exerts renoprotection on an experimental model of LPS-induced AKI.
|
24561306 |
2014 |
|
Kidney Failure, Acute
|
0.400 |
Therapeutic
|
disease |
CTD_human |
Mouse Epo-secreting MSCs were generated, tested in vitro, and then implanted by intraperitoneal injection in allogeneic mice previously administered cisplatin to induce AKI.
|
21847101 |
2011 |